Showing results (81-90 of 126) with videos related to

Sort By:
Pageof 13
The Lancet. Haematology|July 23, 2019
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trialMaria-Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold, et al.
The Lancet. Oncology|April 12, 2025
Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trialMaria-Victoria Mateos, Jesus San-Miguel, Michele Cavo, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 4, 2021
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONEMaria-Victoria Mateos, Meletios A Dimopoulos, Michele Cavo, et al.
Blood|December 28, 2020
Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data setAjai Chari, Mehmet Kemal Samur, Joaquin Martinez-Lopez, et al.
Blood|June 30, 2009
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimensShaji Kumar, Sergio Giralt, Edward A Stadtmauer, et al.
BMC Cancer|June 3, 2021
Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trialStefan Knop, Maria-Victoria Mateos, Meletios A Dimopoulos, et al.
Blood|March 31, 2011
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantationMichele Cavo, S Vincent Rajkumar, Antonio Palumbo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2014
Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related deathPhilippe Moreau, Michele Cavo, Pieter Sonneveld, et al.
The New England Journal of Medicine|June 3, 2015
Elotuzumab Therapy for Relapsed or Refractory Multiple MyelomaSagar Lonial, Meletios Dimopoulos, Antonio Palumbo, et al.
Blood|July 16, 2021
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONEJesus San-Miguel, Hervé Avet-Loiseau, Bruno Paiva, et al.
Pageof 13